| COVID-19 |
1 |
1 |
| Viral Load |
0 |
0.99 |
| Antiviral Agents |
0 |
0.42 |
| HIV Infection |
0 |
0.31 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.28 |
| Patient Safety |
0 |
0.26 |
| Influenza |
0 |
0.25 |
| Vaccines |
0 |
0.18 |
| Tropical Diseases |
0 |
0.16 |
| Zika Virus |
0 |
0.16 |
| Treatment Guidelines |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Obesity |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Type 2 Diabetes Mellitus |
0 |
0.09 |
| Adverse Effects |
0 |
0.07 |
| AIDS |
0 |
0.07 |
| Body Mass Index |
0 |
0.07 |
| California |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Immunization |
0 |
0.07 |
| International Practice of Medicine |
0 |
0.07 |
| Minnesota |
0 |
0.07 |
| Opportunistic Infection |
0 |
0.07 |
| Prediabetes |
0 |
0.07 |